Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Antitumor activity of KEYNOTE158 and CheckMate 358. | Download ...
CheckMate 8HW Trial at ASCO 2025: Nivolumab Plus Ipilimumab Sets New ...
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 ...
CheckMate 358: análise da combinação de nivolumabe (NIVO) e ipilumabe ...
(PDF) Checkmate 274 trial: Is Nivolumab the new standard in adjuvant ...
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients ...
CHECKMATE 358: immunotherapy in combination points to paradigm shift in ...
(PDF) CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline ...
CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and ...
CheckMate 451——Nivolumab和Ipilimumab作为广泛期小细胞肺癌的维持治疗 - 知乎
Supplemental Materials for CheckMate 171: A phase 2 trial of nivolumab ...
Summary of CheckMate Trials Involving Nivolumab | Download Table
| Comparisons between the CheckMate 227 trial and simulation, overall ...
CheckMate 017/057的五年生存结果：Nivolumab在二线非小细胞肺癌治疗中优于多西他赛 - 精选 - 阳光肺科
Thirty-month follow-up of the phase III CheckMate 214 trial of first ...
(PDF) Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate ...
CheckMate 358:Имунотерапия при рецидивирал или метастатичен карцином на ...
Patients' characteristics and outcomes of Checkmate 205 and KEYNOTE-087 ...
Patient characteristics of KEYNOTE158 and CheckMate 358. | Download ...
(PDF) Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell ...
Nivolumab with or without ipilimumab in patients with recurrent or ...
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell ...
2022 ESMO丨CheckMate 358研究：NIVO+IPI可使R/M宫颈癌患者肿瘤持久消退 - 知乎
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV ...
An open-label, multicohort, phase I/II study to evaluate nivolumab in ...
(PDF) Immunotherapy for Uterine Cervical Cancer Using Checkpoint ...
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic ...
(PDF) Neoadjuvant nivolumab for patients with resectable HPV-positive ...
Baseline Patient and Tumor Characteristics | Download Scientific Diagram
Merkel Cell Carcinoma: From Diagnosis to Treatment (webinar) | PPTX
ESMO 2022: Safety and efficacy of nivolumab (NIVO) ± ipilimumab (IPI ...
Tumor Responses According to RECIST, version 1.1 | Download Scientific ...
Nivolumab plus chemotherapy in first-line metastatic non-small-cell ...
Nivolumab versus sorafenib in advanced hepatocellular carcinoma ...
Nivolumab adjuvant therapy for esophageal cancer: a review based on ...
Characterization of Patients with Lymph Node Only Metastatic Urothelial ...
Table 1 from Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma ...
Nivolumab in metastatic urothelial carcinoma after platinum therapy ...
Frontiers | Nivolumab adjuvant therapy for esophageal cancer: a review ...
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus ...
Nivolumab in Patients With Advanced or Metastatic Malignancies ...
Table 1 from Nivolumab Versus Docetaxel in Previously Treated Patients ...
First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung ...
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma ...
CCO_LungIO_Downloadble_Slides_1.pptx
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After ...
宫颈癌已获批上市创新药进展汇总丨单抗、双抗、ADC、组合抗体 宫颈癌2030年是《加速消除宫颈癌全球战略》和《健康中国2030》纲要的共同关键 ...
Nivolumab for muscle-invasive urothelial cancer
Comparative effectiveness of nivolumab versus clinical practice for ...
Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory ...
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma ...
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell ...
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of ...
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced ...
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With ...
Nivolumab in Patients With Advanced Hepatocellular Carcinoma: the ...
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes ...
(PDF) Safety and Efficacy of Nivolumab in Patients With Advanced Clear ...
(PDF) CheckMate-032 Study: Efficacy and Safety of Nivolumab and ...
Health-related Quality of Life with Adjuvant Nivolumab After Radical ...
Efficacy and safety of nivolumab in patients with non-clear cell renal ...
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With ...
How to Integrate Perioperative Immunotherapy Into Multimodal Treatment ...
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab ...
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in ...
Daniel P. Petrylak | New Targets for Advanced Bladder Cancer
Dual Checkpoint Blockade in Merkel Cell Carcinoma: Lessons from ...
Evaluation of tissue- and plasma-derived tumor mutational burden (TMB ...
ESMO 2024: Real-World Characteristics and Outcomes in Patients with ...
Journal of Clinical Images and Medical Case Reports
Safety and efficacy of nivolumab in combination with sunitinib or ...
Table 1 from Adjuvant nivolumab versus placebo following radical ...
Fernanda Musa (@fmusaMD) | Twitter
00088-3/asset/1b2756dd-e77f-45ca-bdf9-d81b544d0ef8/main.assets/gr2_lrg.jpg)
00604-5/asset/29380d69-8674-4ecf-8cec-51084bb93539/main.assets/gr1.gif)
